- Home
- CNX vs JAZZ Comparison
CNX vs JAZZ Comparison
Compare CNX & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNX
- JAZZ
- Stock Information
- Founded
- CNX 1860
- JAZZ 2003
- Country
- CNX United States
- JAZZ Ireland
- Employees
- CNX N/A
- JAZZ N/A
- Industry
- CNX Oil & Gas Production
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- CNX Energy
- JAZZ Health Care
- Exchange
- CNX Nasdaq
- JAZZ Nasdaq
- Market Cap
- CNX 5.5B
- JAZZ 6.5B
- IPO Year
- CNX 1999
- JAZZ 2007
- Fundamental
- Price
- CNX $36.54
- JAZZ $122.49
- Analyst Decision
- CNX Hold
- JAZZ Buy
- Analyst Count
- CNX 12
- JAZZ 14
- Target Price
- CNX $29.45
- JAZZ $173.93
- AVG Volume (30 Days)
- CNX 1.8M
- JAZZ 539.6K
- Earning Date
- CNX 01-23-2025
- JAZZ 11-06-2024
- Dividend Yield
- CNX N/A
- JAZZ N/A
- EPS Growth
- CNX N/A
- JAZZ 458.10
- EPS
- CNX 3.15
- JAZZ 7.04
- Revenue
- CNX $1,369,239,000.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- CNX $8.43
- JAZZ $7.51
- Revenue Next Year
- CNX $15.20
- JAZZ $6.82
- P/E Ratio
- CNX $11.52
- JAZZ $17.38
- Revenue Growth
- CNX N/A
- JAZZ 5.23
- 52 Week Low
- CNX $19.07
- JAZZ $99.06
- 52 Week High
- CNX $41.93
- JAZZ $134.17
- Technical
- Relative Strength Index (RSI)
- CNX 41.77
- JAZZ 53.16
- Support Level
- CNX $36.59
- JAZZ $121.22
- Resistance Level
- CNX $39.04
- JAZZ $126.23
- Average True Range (ATR)
- CNX 1.15
- JAZZ 2.83
- MACD
- CNX -0.41
- JAZZ -0.23
- Stochastic Oscillator
- CNX 14.55
- JAZZ 50.43
About CNX CNX Resources Corporation
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.